Serina Therapeutics Inc (SER)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$2.73+1.49%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Serina Therapeutics leads with a unique polymer drug delivery platform. Analysts expect revenue to double next year. The company is working to fix NYSE compliance and improve finances. Recent stock gains show some investor confidence.
Serina is still losing money with worsening net income. It faces NYSE delisting risks. Funding needs and volatile management raise doubts. The pipeline is unproven and revenue is currently zero.
The price is about 4% below our fair value near $2. Analysts expect 100% revenue growth next year. Our view aligns with this but remains cautious given losses and compliance risks.
Breaks if: NYSE compliance issues remain unresolved past FY26
Breaks if: net loss remains at or worsens beyond -$6.9M by FY26 end
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. SER is currently navigating a volatile management and financial performance environment, which may impact its ability to deliver consistent results in the near term.
The market appears to be pricing in significant challenges, as indicated by the high premium compared to peers. There is an expectations gap suggesting that investors are not fully accounting for the company's recent performance and risks.
Management has made progress on key priorities, such as advancing clinical studies and strengthening financial position through private placements. However, the company remains loss-making and faces a high probability of missing earnings expectations in the near term.
The future trajectory of SER will depend on management's ability to execute on clinical studies and partnerships, as well as the overall health of the healthcare sector. Earnings guidance and macroeconomic factors, such as job reports, will also play a crucial role in shaping investor sentiment.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: no material funding secured by end of FY26
In the next 1 to 3 years, SER's performance will be closely tied to its operational execution and sector dynamics. The current situation warrants careful observation. Not investment advice.